CiVi Biopharma
Christopher Fuglesang is Co-Founder and Managing Director of Boxer Capital, LLC. After joining Tavistock Group in 2005, Dr. Fuglesang helped scale Tavistock Group’s public healthcare investing activities with Boxer Capital. Dr. Fuglesang assists in managing the firm’s research team, deal structuring, and securities compliance.
In addition to CiVi Biopharma, Dr. Fuglesang serves as a Board Observer of Passage Bio and Pandion Therapeutics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
CiVi Biopharma
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.